The global treatment-resistant depression treatment market size was estimated to be USD 1.72 billion in 2023 and is expected to reach at USD 4.60 billion by 2034 with a CAGR of 9.36% during the forecast period 2024-2034. The increasing prevalence of Treatment-Resistant Depression (TRD) has led to various market players concentrating on the development of new and innovative therapies, uptick in research & development efforts aimed at creating advanced drugs for TRD, growing trend of heightened investment in clinical trials for potential pipeline candidates, with the aim of introducing novel products for the treatment of TRD, both public & private entities actively participate in the development of potential candidates undergoing investigational studies are some of the key factors boosting the market growth.
Both public & private entities actively participate in the development of potential candidates undergoing investigational studies is predicted to boost the market growth during the forecast period. Depression is a mental health condition marked by persistent feelings of sadness and a diminished interest in activities. It impacts a person's emotions, thoughts, and behaviors, leading to a range of mental and physical challenges. Antidepressants, pharmaceuticals designed to alleviate symptoms associated with depression, social anxiety disorder, anxiety disorders, and seasonal affective disorder, are one of the treatment options for depression. Individuals classified as having treatment-resistant depression typically include those who are experiencing depression and have not responded positively to at least two trials of antidepressant medications, which may include SSRIs and SNRIs. For instance, in February 2022, Denova Biopharma has received approval from the U.S. FDA to commence a Phase 2b clinical trial, evaluating the effectiveness and safety of DB104 (liafensine) in individuals experiencing treatment-resistant mood disorders.
By drug type, antidepressants was the highest revenue-grossing segment in the global treatment-resistant depression treatment market in 2023 owing to the increase in the occurrence of this mood disorder, leading to a surge in research and development efforts by market players focused on developing antidepressants for its treatment. For instance, in July 2022, Novartis Pharmaceuticals has revealed plans to commence a Phase 2 clinical trial for MIJ821 (ketamine) in the treatment of individuals with treatment-resistant depressive disorders. Additionally, NMDA is predicted to grow at the fastest CAGR during the forecast period owing to the growing emphasis on research studies aimed at developing NMDA drugs to enhance treatment outcomes for a larger patient population affected by this disorder, key market players have received FDA approval for NMDA drugs they have developed, further contributing to advancements in treatment options.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global treatment-resistant depression treatment market in 2023 owing to the growing investment by the public sector in healthcare infrastructure, increase in clinical trial procedures for the launch of novel drugs, and rising approvals by regulatory authorities. In the treatment of this mood disorder, the requirement for prescriptions from medical professionals is a crucial factor contributing to the growth of this segment. For instance, In July 2022, Abbott has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in the treatment of treatment-resistant depression (TRD), which is a form of major depressive disorder (MDD). Additionally, drug stores & retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the rise in patient demand, an increase in the number of drug stores and retail pharmacies, along with increased financial support from governments and other entities, has led to enhanced capitalization for the improvement of retail pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the patient population suffering from treatment-resistant depressive disorder is on the rise, an increasing number of guidelines & drug approvals for treatment, significant research & development investment, and market players are increasingly focused on introducing new drugs for this condition. For instance, in May 2022, COMPASS Pathways unveiled positive data from its Phase IIb study of COMP360 psilocybin therapy for the treatment of treatment-resistant depression during the American Psychiatric Association annual meeting in New Orleans. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the incidence of mood disorders, growing awareness of their treatment, escalating healthcare expenditures, and a surge in research and development activities. For instance, in August 2022, Merck Sharp & Dohme LLC has commenced a Phase II A clinical trial to assess the safety and efficacy of MK-1942 among patients with treatment-resistant depression.
Both public & private entities actively participate in the development of potential candidates undergoing investigational studies is predicted to boost the market growth during the forecast period. Depression is a mental health condition marked by persistent feelings of sadness and a diminished interest in activities. It impacts a person's emotions, thoughts, and behaviors, leading to a range of mental and physical challenges. Antidepressants, pharmaceuticals designed to alleviate symptoms associated with depression, social anxiety disorder, anxiety disorders, and seasonal affective disorder, are one of the treatment options for depression. Individuals classified as having treatment-resistant depression typically include those who are experiencing depression and have not responded positively to at least two trials of antidepressant medications, which may include SSRIs and SNRIs. For instance, in February 2022, Denova Biopharma has received approval from the U.S. FDA to commence a Phase 2b clinical trial, evaluating the effectiveness and safety of DB104 (liafensine) in individuals experiencing treatment-resistant mood disorders.
By drug type, antidepressants was the highest revenue-grossing segment in the global treatment-resistant depression treatment market in 2023 owing to the increase in the occurrence of this mood disorder, leading to a surge in research and development efforts by market players focused on developing antidepressants for its treatment. For instance, in July 2022, Novartis Pharmaceuticals has revealed plans to commence a Phase 2 clinical trial for MIJ821 (ketamine) in the treatment of individuals with treatment-resistant depressive disorders. Additionally, NMDA is predicted to grow at the fastest CAGR during the forecast period owing to the growing emphasis on research studies aimed at developing NMDA drugs to enhance treatment outcomes for a larger patient population affected by this disorder, key market players have received FDA approval for NMDA drugs they have developed, further contributing to advancements in treatment options.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global treatment-resistant depression treatment market in 2023 owing to the growing investment by the public sector in healthcare infrastructure, increase in clinical trial procedures for the launch of novel drugs, and rising approvals by regulatory authorities. In the treatment of this mood disorder, the requirement for prescriptions from medical professionals is a crucial factor contributing to the growth of this segment. For instance, In July 2022, Abbott has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in the treatment of treatment-resistant depression (TRD), which is a form of major depressive disorder (MDD). Additionally, drug stores & retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the rise in patient demand, an increase in the number of drug stores and retail pharmacies, along with increased financial support from governments and other entities, has led to enhanced capitalization for the improvement of retail pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the patient population suffering from treatment-resistant depressive disorder is on the rise, an increasing number of guidelines & drug approvals for treatment, significant research & development investment, and market players are increasingly focused on introducing new drugs for this condition. For instance, in May 2022, COMPASS Pathways unveiled positive data from its Phase IIb study of COMP360 psilocybin therapy for the treatment of treatment-resistant depression during the American Psychiatric Association annual meeting in New Orleans. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the incidence of mood disorders, growing awareness of their treatment, escalating healthcare expenditures, and a surge in research and development activities. For instance, in August 2022, Merck Sharp & Dohme LLC has commenced a Phase II A clinical trial to assess the safety and efficacy of MK-1942 among patients with treatment-resistant depression.
Segmentation: Treatment-Resistant Depression Treatment Market Report 2023 - 2034
Treatment-Resistant Depression Treatment Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- Antipsychotics
- NMDA
- Antidepressants
- Others
Treatment-Resistant Depression Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Online Pharmacies
- Drug Stores & Retail Pharmacies
Treatment-Resistant Depression Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Treatment-Resistant Depression Treatment Market: Drug Type Estimates & Trend Analysis
8. Treatment-Resistant Depression Treatment Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Treatment-Resistant Depression Treatment Market
11. Europe Global Treatment-Resistant Depression Treatment Market
12. Asia Pacific Global Treatment-Resistant Depression Treatment Market
13. Latin America Global Treatment-Resistant Depression Treatment Market
14. MEA Global Treatment-Resistant Depression Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Otsuka Pharmaceutical Co. Ltd. (Otsuka Holdings Co. Ltd.)
- Janssen Global Services Llc (Johnson & Johnson Services Inc.)
- Par Pharmaceutical (Endo International plc)
- Sandoz International GmbH (Novartis AG)
- Eli Lilly and Company
- H. Lundbeck A/S
- GlaxoSmithKline
- AstraZeneca
- AbbVie Inc.
- Pfizer Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.72 Billion |
| Forecasted Market Value ( USD | $ 4.6 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
